Premium
Regression of established subcutaneous B16‐F10 murine melanoma tumors after gef gene therapy associated with the mitochondrial apoptotic pathway
Author(s) -
Prados Jose,
Melguizo Consolación,
Ortiz Raúl,
Boulaiz Houria,
Carrillo Esmeralda,
Segura Ana,
RodríguezHerva Jose Juan,
Ramos Juan Luis,
Aránega Antonia
Publication year - 2010
Publication title -
experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.108
H-Index - 96
eISSN - 1600-0625
pISSN - 0906-6705
DOI - 10.1111/j.1600-0625.2009.00914.x
Subject(s) - melanoma , in vivo , apoptosis , genetic enhancement , cancer research , in vitro , gene , medicine , programmed cell death , cancer , suicide gene , biology , genetics
Please cite this paper as: Regression of established subcutaneous B16‐F10 murine melanoma tumors after gef gene therapy associated with the mitochondrial apoptotic pathway. Experimental Dermatology 2009. Abstract: Novel treatment modalities, including gene therapy, are needed for patients with advanced melanoma. We evaluated whether the gef gene, a suicide gene from Escherichia coli, had a significant cytotoxic impact on melanoma in vivo . First, we used a non‐viral gene delivery approach (pcDNA3.1/ gef ) to study the inhibition of melanoma cells (B16‐F10) proliferation in vitro . Secondly, we used direct intra‐tumoral injection of pcDNA3.1/ gef complexed with jetPEI to deliver gef cDNA to rapidly growing murine melanomas. We demonstrated that gef gene not only has an antiproliferative effect on B16‐F10 cells in vitro, but also induces an important decrease in melanoma tumor volume (77.7% in 8 days) in vivo . Interestingly, after gef gene treatment, melanoma showed apoptosis activation associated with the mitochondrial pathway, suggesting that the induction of this death mechanism may be an effective strategy for its treatment. Our in vivo results indicate that gef gene might become a suitable therapeutic strategy for patients with advanced melanoma.